Enoxaparin-induced hepatotoxicity: clinical cases and literature review
https://doi.org/10.21292/2078-5658-2021-18-1-84-92
Abstract
Low molecular weight heparins, in particular enoxaparin, have a wide range of applications, including prevention and treatment of deep vein thrombosis. The most common adverse effects of these drugs are bleeding and thrombocytopenia, but a clinician should be aware of another less common but not less important adverse effect such as an elevated transaminase level. In 2019, we observed two cases of enoxaparin-induced hepatotoxicity. In the first one, enoxaparin 0.4 ml subcutaneously twice a day was prescribed to a 40-year-old woman as a bridge therapy to discontinue warfarin before elective surgery. In the second case, a 27-year-old man received enoxaparin 0.4 ml subcutaneously twice a day for the prevention of deep vein thrombosis. The elevation of transaminase level for more than 3 times above the norm was noted in both patients which required discontinuation of the drug.
About the Authors
Yu. N. Krovko
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Yulia N. Krovko Resident Physician of Anesthesiology and Intensive Care Department
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
A. V. Shmigelskiy
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Aleksandr V. Shmigelskiy Doctor of Medical Sciences, Professor
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
A. D. Аkhmedov
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Ayaz Dzh. Аkhmedov Candidate of Medical Sciences, Neurosurgeon
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
A. A. Shulgina
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Anna A. Shulgina Neurosurgeon, Post-Graduate Student of Neurosurgery Department no.4
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
V. A. Lukshin
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Vasiliy A. Lukshin Doctor of Medical Sciences, Associate Professor
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
D. Yu. Usachev
N.N. Burdenko National Scientific and Practical Center for Neurosurgery
Russian Federation
Russian Federation
Dmitry Yu. Usachev Doctor of Medical Sciences, Professor, Correspondent Member of the Russian Academy of Sciences, Director of the Center
16, 4th Tverskaya-Yamskaya St., Moscow, 125047
Phone: +7 (499) 972–86–68
References
1. State Register of Medications. Guidelines for medical use of Hepabene. (In Russ.) (Epub.), Available: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1629b696-7bc5-422b-a3ef-ee4eb400fde3&t= (Accessed: 19.01.2020).
2. State Register of Medications. Guidelines for medical use of Ursosan. (In Russ.) (Epub.), Available: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=75ee02eb-a348-49eb-bd05-d74f693f081a&t= (Accessed: 19.01.2020).
3. State Register of Medications. Use guidelines for Kreon 25000. (In Russ.) (Epub.), Available: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8ac439cc-d78c-4d8f-9ffe-a085984979fb&t= (Accessed: 19.01.2020).
4. Ivashkin V. T., Baranovskiy А. Yu., Raykhelson K. L.et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossiyskiy Journal Gastroenterologii, Gepatologii, Koloproktologii, 2019, vol. 29, no. 1, pp. 101-131. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-1-101-131.
5. Pimanov S.I., Makarenko E.V. Idiosyncratic drug-induced liver injury: diagnosis and treatment. Meditsinsky Soviet, 2017, no. 5, pp. 100-107. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-100-107.
6. Arora N., Goldhaber S.Z. Anticoagulants and transaminase elevation. Circulation, 2006, vol. 113, no. 15, pp. 698‒702. https://doi.org/10.1161/CIRCULATIONAHA.105.603100.
7. Baker E.L., Loewenthal T., Salerno E. et al. Probable enoxaparin-induced hepatotoxicity. Am. J. Heal. Pharm., 2009, vol. 66, no. 7, pp. 638‒641. https://doi.org/10.2146/ajhp080311.
8. Bosco M., Kish T. Hepatotoxicity with elevated bilirubin secondary to prophylactic doses of unfractionated heparin: a case report and review of heparin-induced hepatotoxicity. J. Pharm. Technol., 2019, vol. 35, no. 1, pp. 36‒40. https://doi.org/10.1177/8755122518803363.
9. Cano-Paniagua A., Amariles P., Angulo N. et al. Epidemiology of drug-induced liver injury in a University Hospital from Colombia: updated RUCAM being used for prospective causality assessment. Ann. Hepatol., 2019, vol. 18, no. 3, pp. 501‒507. https://doi.org/10.1016/j.aohep.2018.11.008.
10. Carlson M.K., Gleason P.P., Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity.
11. Pharmacotherapy, 2001, vol. 21, no. 1, pp. 108‒113. https://doi.org/10.1592/phco.21.1.108.34436.
12. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: the update. Int. J. Mol. Sci., 2015, vol. 17, no. 1, pp. 1‒33. https://doi.org/10.3390/ijms17010014.
13. Di Saia P.J., Creasman W.T., Mannel R.S. et al. Clinical Gynecologic Oncology 9th edition. Philadelphia, PA, Elsevier, Inc., 2018, pp. 1‒631.
14. Faraoni D., Comes R.F., Geerts W. et al. European guidelines on perioperative venous thromboembolism prophylaxis. Eur. J. Anaesthesiol., 2018, vol. 35, no. 2, pp. 90‒95. https://doi.org/10.1097/EJA.0000000000000710.
15. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. 2009, pp. 1-25. (Epub.), Available: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/147533/qh-gdl-951.pdf (Accessed: 19.01.2020).
16. Guideline for anticoagulation and prophylaxis using low molecular weight heparin (LMWH) in adult inpatients. 2016, pp. 1‒15. (Epub.), Available: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/147533/qh-gdl-951.pdf (Accessed 19.01.2020).
17. Hahn K.J., Morales S.J., Lewis J.H. Enoxaparin-induced liver injury: case report and review of the literature and FDA adverse event reporting system (FAERS). Drug. Saf., 2015, vol. 2, no. 1, pp. 1‒11. https://doi.org/10.1007/s40800-015-0018-0.
18. Harrill A.H., Roach J., Fier I. et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin. Pharmacol. Ther., 2012, vol. 92, no. 2, pp. 214‒220. https://doi.org/10.1038/clpt.2012.40.
19. Hayashi P.H., Rockey D.C., Fontana R.J. et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology, 2017, vol. 66, no. 4, pp. 1275‒1285. https://doi.org/10.1002/hep.29283.
20. Hoofnagle J.H., Björnsson E.S. Drug-induced liver injury-types and phenotypes. N. Engl. J. Med., 2019, vol. 381, no. 3, pp. 264‒273. https://doi.org/10.1056/NEJMra1816149.
21. .Hui C., Yuen M., Ng I.O. et al. Low molecular weight heparin-induced liver toxicity. J. Clin. Pharmacol., 2001, vol. 41, pp. 691‒694. https://doi.org/10.1177/00912700122010465.
22. Kleiner D.E., Chalasani N.P., Lee W.M. et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology, 2014, vol. 59, no. 2, pp. 661‒670. https://doi.org/10.1002/hep.26709.
23. Leo M., Ponziani F.R., Nesci A. et al. Low molecular weight heparin as cause of liver injury: case report and literature review. Eur. Rev. Med. Pharmacol. Sci., 2019, vol. 23, no. 17, pp. 7649‒7654. https://doi.org/10.26355/eurrev_201909_18888.
24. Nguyen A., Dasgupta A., Wahed A. Management of hemostasis and coagulopathies for surgical and critically ill patients: an evidence-based approach 1st edition. Elsevier, Inc., 2016, pp. 1-174.
25. Nissenson A.R., Fine R.N. Handbook of dialysis therapy. Philadelphia, PA. Elsevier, Inc., 2017, pp. 1‒1171.
26. Robles-Diaz M., Isabel Lucena M., Kaplowitz N. et al. Use of hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology, 2014, vol. 147, no. 1, pp. 109‒118.e5. https://doi.org/10.1053/j.gastro.2014.03.050.
27. Sonnenblick M., Oren A., Jacobsonn W. Hyper-transaminasemia with heparin therapy. Br. Med. J., 1975, vol. 3, pp. 77. https://doi.org/10.1136/bmj.3.5975.77.
28. Thakkar S., Li T., Liu Z. et al. Drug-induced liver injury severity and toxicity (DILIst): binary classification of 1279 drugs by human hepatotoxicity. Drug. Discov. Today, 2019, vol. 25, no. 1, pp. 201‒208. https://doi.org/10.1016/j.drudis.2019.09.022.
29. Watkins P.B. Idiosyncratic drug-induced liver injury in patients: detection, severity assessment, and regulatory implications 1st edition. Advanc. Pharmacol., 2019, vol. 85, pp. 165‒193. https://doi.org/10.1016/bs.apha.2019.02.004
Review
For citations:
Krovko Yu.N., Shmigelskiy A.V., Аkhmedov A.D., Shulgina A.A., Lukshin V.A., Usachev D.Yu. Enoxaparin-induced hepatotoxicity: clinical cases and literature review. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2021;18(1):84-92. (In Russ.) https://doi.org/10.21292/2078-5658-2021-18-1-84-92
Email this article 